Update on the treatment of primary immunodeficiencies

Allergologia et Immunopathologia

Volumn 35, Issue 5, 2007, Pages 184-192

  García Martínez, Juan M ^a   Espanol T ^b   Gurbindo, Ma D ^c   Casas C, C ^d,e  

^a HOSPITAL DE CRUCES   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e Immunology Group   (Spain)

Author keywords

Gammaglobulin therapy; Gene therapy; Primary immunodeficiency; Severe combined immunodeficiency; Stem cell transplantation

Indexed keywords

ANTIINFECTIVE AGENT; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; VIRUS VECTOR;

ABDOMINAL PAIN; ADENOVIRUS; ANAPHYLAXIS; ARTHRALGIA; ATAXIA TELANGIECTASIA; BONE MARROW; CELL COUNT; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DONOR; DONOR SELECTION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; GENE; GENE INSERTION; GENE THERAPY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC CELL; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HOME; HOST; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION; KINETICS; LAMINAR FLOW; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MEASLES; MODULATION; NAUSEA; ONCOLOGY; PHAGOCYTE; PHAGOCYTOSIS; PROGNOSIS; PROPHYLAXIS; PROTO ONCOGENE; QUALITY OF LIFE; RABIES; RETROVIRUS; REVIEW; RIGOR; RISK; STEM CELL; STEM CELL TRANSPLANTATION; SYMPTOM; T CELL DEPLETION; TETANUS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; UMBILICAL CORD BLOOD; URTICARIA; VIRUS INFECTION; VIRUS REPLICATION; VOMITING; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; X LINKED AGAMMAGLOBULINEMIA; X LINKED LYMPHOPROLIFERATIVE SYNDROME;

EID: 35348864622     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13110313     Document Type: Article

References (65)

1. Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: general considerations. In: Stiehm ER, ed. Immunologic Disorders in Infants and Children. 5th ed. Philadelphia: WB Elsevier-Saunders; 2004. p. 289-355.
2. Medical Research Council Working Party. Hypogammaglobulinemia in the United Kingdom. Lancet. 1969;1:163-9.
3. Bjoro K, Froland SS, Yun Z, Samdal H H, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. New Engl J Med. 1994;331:1607-11.
4. Montanaro A, Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med. 1984;76:67-72.
5. Ochs Hd, Fischer SH, Wedgwood R, Wara D W, Cowan MJ, Ammann AJ, et al.. Comparison of high dose and low dose intravenous immunoglobulin therapy in patients with primary immunodeficiency disease. Am J Med. 1984;76:78-82.
6. Kato E, Eto Y, HashimotoN, Yamamoto M, Sakata Y. Hiyoshi Y. Administration of immune globulin associated with aseptic meningitis. JAMA. 1988;259:3267-71.
7. Vera-Ramirez M, Charlet M, Parry GJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1992;42:1636-7.
8. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1991;36:83-6.
9. Brox AG, Courmoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous immunoglobulin administration. Am J Med. 1987;83:633-5.
10. Horn J, Thon V, Bartonkova D, Salzer U, Warnatz K, Schlesier M, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007;122:156-62.
11. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Costa-Carvalho B et al. Children and adults with primary antibody deficiencias gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114: 936-42.
12. Steward, C G. Jarisch, A. Haemopoietic stem cell transplantation for genetic disorders. Arch Dis Childh. 2005;90:1259-63.
13. Español, T. Substitution therapy with hematopoietic progenitors in the primary immunodeficiencies. Allergol et Immunopathol. 2001;29:118-21.
14. Madero L. Trasplante de médula ósea en inmunodeficiencias primarias. Allergol et Immunopathol. 2006;34 Suppl 1:38-45.
15. O'Reilly RJ, Small TN, Friedrich W. Hematopoietic cell transplant for immunodeficiency diseases. Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic cell transplantation, 2nd ed. Blackwell Sc. Malden; 2004. p. 1430-42.
16. Copelan EA. Medical progress: Haematopoietic stem-cell transplantation. N Eng J Med. 2006;354:1813-26.
17. Rosen FS. Severe combined immunodeficiency. A pediatric emergency. J Pediatr. 1997;130:345-6.
18. Buckley RH. Treatment options for genetically determined immunodeficiency. Lancet. 2003;361:541-2.
19. Friedrich W, Honig M, Schulz A, Muller SM. Immune reconstitution in congenital disorders after HLA-haploidentical hemopoietic stem cell transplantation. Blood Cells Molecules Dis. 2004;33:291-3.
20. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G et al. Long term immune reconstitution and outcome after HLA-non-identical T-cell depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients. Blood. 1998;91:3646-53.
21. Bertrand Y, Landais P, Friedrich W, Gerritsen B, Morgan G, Fasth A et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatrics. 1999;134:740-8.
22. Martín MP, Arrieta R, Martínez A, García P, Jiménez-Yuste V, Hernández-Navarro F et al. Haploidentical peripheral blood stem cell transplantation with a combination of CD34 selection and T cell depletion as graft versus host prophylaxis in a patient with severe combined immunodeficiency. Bone Marrow Transplant. 1997;20:797-9.
23. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood. 2001;97:2957-61.
24. Alegre A, Diaz MA, Madero L, Granda A, de la Vega A, Villa M et al. Large volume leukapheresis for peripheral blood stem cell collection in children: a simplified single apheresis approach. Bone Marrow Transplant. 1996;17:923-7.
25. Rice HE. Skinner MA. Mahaffey S Oldham KT, Ing RJ, Hale LP et al. Thymic transplantation for complete DiGeorge syndrome: medical and surgical considerations. J Pediat Surg. 2004;39:1607-15.
26. Sale GE. Pathogenesis of graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:21-3.
27. a ed. Madrid: Ergón; 2005. p. 371-93. (Grados de EICH).
28. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. 2004;364:156-62.
29. Bone marrow transplantation and gene therapy. http://www.esid.org/ downloads/BMT Guidelines_old.doc
30. Slavin S. Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation. Lancet. 2004;364:122-4.
31. Mc Cann SR, Crampe M, Molloy K, Lawler M. Hematopoietic chimerism following stem cell transplantation. Transfus Apheresis Sci. 2005;32:55-61.
32. Fischer A, Le Deist F, Hacein-Bey-Alina S, Andre-Schmutz J, de San Basile G et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunological Reviews. 2005;203:98-109.
33. Buckley R, Schiff SE, Sampson HA, Schiff RI, Markert ML, Knutsen AP et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol. 1986;136:2398-407.
34. Wijnaendts L, Le Deist C, Gricelli C, Fischer A Development of immunologic functions after bone marrow transplantation in 33 patients with severe combined immunodeficiency. Blood. 1998;72:408A.
35. Tsuji Y, Imai K, Kajiwara M, Aoki Y, Isoda T, Tomizawa D et al. Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. Bone Marrow Transplant. 2006;37:469-77..
36. Madero L, Villa M. [Bone marrow transplantation in the primary immunodeficiecies]. Sangre. 1999;44:135-41.
37. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361:553-60.
38. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508-16.
39. Kane L, Gennery AR, Crooks BNA, Flood TJ, Abinum M, Cant AJ. Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed. 2001;85:F110-3.
40. Hebart H, Einsele H. Specific infectious complications after stem cell transplantation. Support Care Cancer. 2004;12:80-5.
41. Brennan B, Shalet, SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002;118:58-66.
42. Leiper AD. Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol. 2002;118:3-22.
43. Leiper AD. Non-endocrine late complications of bone marrow transplantation in childhood: part II. Br J Haematol 2002;118:23-43.
44. Badell I, Igual L, Gómez P, Bureo E, Ortega JJ, Cubells J et al. Quality of life in young adults having received a BMT during childhood: a GETMON study. Grupo Español de Trasplante de Médula Ósea en el Niño. Bone Marrow Transplant. 1998;21:S68-71.
45. Candotti F, Fischer A. Gene therapy. In: Primary immunodeficiency diseases. A molecular and genetic approach. Oxford University press. New York; 2007. p. 688-705.
46. Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Therapy. 2006;13:1313-9.
47. Notarangelo L, Casanova JL, Fischer A, Puck J, Rosen F, Seger R et al. International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary Immunodeficiency Diseases. An update. J Allergy Clin Immunol. 2004;114:677-87.
48. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M et al. T-lymphocte directed gene therapy for ADASCID: initial trial results after 4 years. Science 1995;270:475-80.
49. Fischer A. Primary Immunodeficiency diseases: an experimental model for molecular medicine. Lancet. 2001;357:1863-9.
50. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartey JP, et al Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.. N Engl J Med. 2002;346:1241-3.
51. Aiuti A, Vai S, Mortellano A, Casorati G, Ficara F, Andolfi G, et al. Immune reconstitution in ADA-SCPI after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8:423-5.
52. Kaiser J. Retroviral vectors: a double-edged sword. Science 2005; 308:1735-6.
53. Baum C, Düllman J, Li Z et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;104:2099-113.
54. Lee H, Koehler DR, Pang CY, Levine RH, Palmer DJ, Quinton PM, Hu J. Gene delivery to human sweat glands: a model for cystic fibrosis gene therapy. Gene Ther. 2007;14:281.
55. Hacein-Bey-Abina S, von Kalle C, Schmidt M, LeDeist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-6.
56. Chinen J, Puck J. Successes and risks of gene therapy in primary immunodeficiencies. J. Allergy Clin Immunol. 2004;113:595-603.
57. Toloza EM. Gene therapy for lung cancer. Thorac Surg Clin. 2006;16:397-419.
58. Belousova N, Korokhov N, Krendelshchikova V, Soimonenko V, Mikheeva G, Triozi PL, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol. 2003;77:11367-77.
59. Griesenbach U, Geddes DM, Galton EWFW, on behalf of the UK Cystic Fibrosis gene therapy Consortium. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 2006;13: 061-7.
60. Gan SU, Calne RY. Gene therapy for hemophilia A. Discov Med. 2006;6:198-202
61. Anson DS, McIntyre C, Thomas B, Koldej R, Ranieri E, Roberts A, Clements PR, Dunning K, Byers S. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Genet Vaccines Ther. 2007;5:1.
62. Sakuma R, Noser JA, Ohmine S and Ikeda Y. Inhibition of HIV-1 replication by simian restriction factors, TRIM5a and APOBEC3G. Gene Ther. 2007;14:185-9.
63. Stein S, Siler U, Ott MG, Seger R, Grez M. Gene therapy for chronic granulomatous disease. Curr Opin Mol Ther. 2006;8:415-22.
64. Evans CH. Gene therapy. What have we accomplished and where do we go from here? J Rheumatology. 2005;32:17-20.
65. Condotti F, Roifman C, Puck JM. Immunodeficiencies: injecting some safety into SCID gene therapy. Gene Ther. 2006;13:741-3.